Abstract | PURPOSE: MATERIALS AND METHODS: From 2000 to 2004, 207 COPD patients who underwent spirometry before and after inhalation of 400 microg of fenoterol were analyzed. A responder to the bronchodilator test ( BDT) was defined by the American Thoracic Society (ATS) as an increase in forced expiratory volume in one second (FEV(1)) or forced vital capacity > or = 12% and > or = 200 mL, and by the European Respiratory Society (ERS) as an increase in FEV(1) > or = 10% of the predicted value. COPD severity was classified according to the 2008 GOLD guidelines. RESULTS: For the entire study population, the FEV(1) increased by 11.8 +/- 12.5% of baseline after BDT and 41.1% and 27.1% of subjects were classified as responders using the ATS and ERS criteria, respectively. Based on pre- BDT spirometry, 55, 85, 58, and 9 patients were classified as Stage I-IV COPD, respectively. Sixty-seven (32.4%) patients changed severity staging after BDT, including 20.0%, 28.2%, 44.8%, and 66.7% of pre- BDT patients Stages I through IV, respectively. More ATS or ERS BDT-responders had a change in severity staging than non-responders (52.9% vs. 18.9% and 62.5% vs. 21.2%, both p < 0.001). CONCLUSION: Our data suggest that the severity staging of COPD using pre- BDT spirometry might lead to significant differences as compared to staging, based on post- BDT spirometry, as recommended by the current GOLD guidelines.
|
Authors | Sheng-Hsiang Lin, Ping-Hung Kuo, Sow-Hsong Kuo, Pan-Chyr Yang |
Journal | Yonsei medical journal
(Yonsei Med J)
Vol. 50
Issue 5
Pg. 672-6
(Oct 31 2009)
ISSN: 1976-2437 [Electronic] Korea (South) |
PMID | 19881971
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Bronchodilator Agents
- Fenoterol
|
Topics |
- Bronchodilator Agents
- Fenoterol
- Forced Expiratory Volume
(drug effects)
- Humans
- Practice Guidelines as Topic
- Prognosis
- Pulmonary Disease, Chronic Obstructive
(diagnosis)
- Spirometry
(methods)
|